## Kristian Wahlbeck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8978432/publications.pdf

Version: 2024-02-01

			3	30070	29	157
	155	11,735		54		104
p	apers	citations		h-index		g-index
	162	162		162		12286
a	ll docs	docs citatio	ns	times ranked		citing authors

#	Article	IF	CITATIONS
1	Finding the right words: Articulating the value of mental health promotion. A focus group study. Journal of Community Psychology, 2022, 50, 2857-2874.	1.8	1
2	Life Conditions as Mediators of Welfare State Effect on Mental Wellbeing among Oldest Old in Europe. International Journal of Environmental Research and Public Health, 2022, 19, 4363.	2.6	1
3	†Îf we would change things outside we wouldn't even need to go in†¦â€™ supporting recovery via communityâ€based actions: A focus group study on psychiatric rehospitalization. Health Expectations, 2021, 24, 174-184.	2.6	3
4	Is Mental Well-Being in the Oldest Old Different from That in Younger Age Groups? Exploring the Mental Well-Being of the Oldest-Old Population in Europe. Journal of Happiness Studies, 2021, 22, 1693-1717.	3.2	7
5	Using national electronic health care registries for comparing the risk of psychiatric re-hospitalisation in six European countries: Opportunities and limitations. Health Policy, 2019, 123, 1028-1035.	3.0	14
6	The Economic Case for the Prevention of Mental Illness. Annual Review of Public Health, 2019, 40, 373-389.	17.4	119
7	Identifying Local and Centralized Mental Health Servicesâ€"The Development of a New Categorizing Variable. International Journal of Environmental Research and Public Health, 2018, 15, 1131.	2.6	14
8	A Comparison of Mental Health Care Systems in Northern and Southern Europe: A Service Mapping Study. International Journal of Environmental Research and Public Health, 2018, 15, 1133.	2.6	40
9	Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry, 2017, 16, 30-40.	10.4	477
10	Psychiatric readmissions and their association with physical comorbidity: a systematic literature review. BMC Psychiatry, 2017, 17, 2.	2.6	141
11	Interventions to mitigate the effects of poverty and inequality on mental health. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 505-514.	3.1	63
12	National funding for mental health research in Finland, France, Spain and the United Kingdom. European Neuropsychopharmacology, 2017, 27, 892-899.	0.7	13
13	Antidepressant use and violent crimes among young people: a longitudinal examination of the Finnish 1987 birth cohort. Journal of Epidemiology and Community Health, 2017, 71, 12-18.	3.7	16
14	The Impact of the 2008 Economic Crisis on Substance Use Patterns in the Countries of the European Union. International Journal of Environmental Research and Public Health, 2016, 13, 122.	2.6	74
15	Regional Correlates of Psychiatric Inpatient Treatment. International Journal of Environmental Research and Public Health, 2016, 13, 1204.	2.6	7
16	How size matters: exploring the association between quality of mental health services and catchment area size. BMC Psychiatry, 2016, 16, 289.	2.6	12
17	Psychiatric readmissions and their association with environmental and health system characteristics: a systematic review of the literature. BMC Psychiatry, 2016, 16, 376.	2.6	54
18	Statistical methods and modelling techniques for analysing hospital readmission of discharged psychiatric patients: a systematic literature review. BMC Psychiatry, 2016, 16, 413.	2.6	5

#	Article	IF	Citations
19	Research priorities for public mental health in Europe: recommendations of the ROAMER project. European Journal of Public Health, 2015, 25, 249-254.	0.3	113
20	Contribution of the Nordic School of Public Health to the public mental health research field: a selection of research initiatives, 2007–2014. Scandinavian Journal of Public Health, 2015, 43, 66-72.	2.3	6
21	Mental health and alcohol use: a cross-sectional study of the Finnish general population. European Journal of Public Health, 2015, 25, 225-231.	0.3	54
22	Public mental health: the time is ripe for translation of evidence into practice. World Psychiatry, 2015, 14, 36-42.	10.4	136
23	Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study. Journal of Affective Disorders, 2015, 183, 159-165.	4.1	58
24	Mental health research priorities for Europe. Lancet Psychiatry, the, 2015, 2, 1036-1042.	7.4	158
25	Cross-national variations in reported discrimination among people treated for major depression worldwide: The ASPEN/INDIGO international study. British Journal of Psychiatry, 2015, 207, 507-514.	2.8	47
26	Developing a tool for mapping adult mental health care provision in Europe: the REMAST research protocol and its contribution to better integrated care. International Journal of Integrated Care, 2015, 15, e042.	0.2	33
27	Public mental health and suicide. , 2015, , 1013-1027.		1
28	Prenatal and Childhood Growth, and Hospitalization for Alcohol Use Disorders in Adulthood: The Helsinki Birth Cohort Study. PLoS ONE, 2014, 9, e87404.	2.5	3
29	Size Matters — Determinants of Modern, Community-Oriented Mental Health Services. International Journal of Environmental Research and Public Health, 2014, 11, 8456-8474.	2.6	17
30	Does Primary Care Mental Health Resourcing Affect the Use and Costs of Secondary Psychiatric Services?. International Journal of Environmental Research and Public Health, 2014, 11, 8743-8754.	2.6	12
31	Towards Horizon 2020: challenges and advances for clinical mental health research & mp; ndash; outcome of an expert survey. Neuropsychiatric Disease and Treatment, 2014, 10, 1057.	2.2	20
32	Public mental health research in Europe: a systematic mapping for the ROAMER project. European Journal of Public Health, 2014, 24, 955-960.	0.3	25
33	Twentyâ€eight years after the complete ban on the physical punishment of children in Finland: Trends and psychosocial concomitants. Aggressive Behavior, 2014, 40, 568-581.	2.4	35
34	ROAMER: roadmap for mental health research in Europe. International Journal of Methods in Psychiatric Research, 2014, 23, 1-14.	2.1	109
35	Nature and impact of European anti-stigma depression programmes. Health Promotion International, 2014, 29, 403-413.	1.8	16
36	Structural and Cognitive Aspects of Social Capital and All-Cause Mortality: A Meta-Analysis of Cohort Studies. Social Indicators Research, 2014, 116, 545-566.	2.7	85

#	Article	IF	CITATIONS
37	Associations between problem gambling, socio-demographics, mental health factors and gambling type: sex differences among Finnish gamblers. International Gambling Studies, 2014, 14, 39-52.	2.1	16
38	Social capital and reported discrimination among people with depression in 15 European countries. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 1589-1598.	3.1	15
39	Maternal Grand Multiparity and the Risk of Severe Mental Disorders in Adult Offspring. PLoS ONE, 2014, 9, e114679.	2.5	21
40	Global pattern of experienced and anticipated discrimination reported by people with major depressive disorder: a cross-sectional survey. Lancet, The, 2013, 381, 55-62.	13.7	331
41	Patterns in mortality among people with severe mental disorders across birth cohorts: a register-based study of Denmark and Finland in 1982–2006. BMC Public Health, 2013, 13, 834.	2.9	40
42	Experiences with treating immigrants: a qualitative study in mental health services across 16 European countries. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 105-116.	3.1	91
43	Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open, 2013, 3, e002373.	1.9	154
44	Socioeconomic and regional aspects in the use of specialized psychiatric careâ€"a Finnish nationwide follow-up study. European Journal of Public Health, 2013, 23, 372-377.	0.3	29
45	Suicide mortality trends in the Nordic countries 1980–2009. Nordic Journal of Psychiatry, 2013, 67, 414-423.	1.3	58
46	Excess Mortality, Causes of Death and Life Expectancy in 270,770 Patients with Recent Onset of Mental Disorders in Denmark, Finland and Sweden. PLoS ONE, 2013, 8, e55176.	2.5	486
47	Life Expectancy and Death by Diseases of the Circulatory System in Patients with Bipolar Disorder or Schizophrenia in the Nordic Countries. PLoS ONE, 2013, 8, e67133.	2.5	250
48	Substance-Induced Psychoses Converting Into Schizophrenia. Journal of Clinical Psychiatry, 2013, 74, e94-e99.	2.2	163
49	Actions to alleviate the mental health impact of the economic crisis. World Psychiatry, 2012, 11, 139-145.	10.4	167
50	Temporary Separation from Parents in Early Childhood and Serious Personality Disorders in Adult Life. Journal of Personality Disorders, 2012, 26, 751-762.	1.4	17
51	How does a history of psychiatric hospital care influence access to coronary care: a cohort study. BMJ Open, 2012, 2, e000831.	1.9	13
52	Successful deinstitutionalization of mental health care: increased life expectancy among people with mental disorders in Finland. European Journal of Public Health, 2012, 22, 604-606.	0.3	21
53	Structural and cognitive social capital and depression among older adults in two Nordic regions. Aging and Mental Health, 2012, 16, 771-779.	2.8	98
54	Hypertensive disorders in pregnancy and risk of severe mental disorders in the offspring in adulthood: The Helsinki Birth Cohort Study. Journal of Psychiatric Research, 2012, 46, 303-310.	3.1	64

#	Article	IF	CITATIONS
55	O27. Hypertensive disorders in pregnancy and risk of severe mental disorders in the offspring in adulthood: The Helsinki Birth Cohort study. Pregnancy Hypertension, 2011, 1, 271.	1.4	1
56	Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. British Journal of Psychiatry, 2011, 199, 453-458.	2.8	448
57	European mental health policy should target everybody. European Journal of Public Health, 2011, 21, 551-553.	0.3	9
58	Risk of severe mental disorders in adults separated temporarily from their parents in childhood: The Helsinki birth cohort study. Journal of Psychiatric Research, 2011, 45, 332-338.	3.1	66
59	Glucocorticoid receptor gene haplotype predicts increased risk of hospital admission for depressive disorders in the Helsinki birth cohort study. Journal of Psychiatric Research, 2011, 45, 1160-1164.	3.1	16
60	Incidence of hospitalised schizophrenia in Finland since 1980: decreasing and increasing again. Social Psychiatry and Psychiatric Epidemiology, 2011, 46, 343-350.	3.1	19
61	Personal stigma and use of mental health services among people with depression in a general population in Finland. BMC Psychiatry, 2011, 11, 52.	2.6	88
62	Good practice in health care for migrants: views and experiences of care professionals in 16 European countries. BMC Public Health, 2011, 11, 187.	2.9	217
63	Reported Stigma and Discrimination by People with a Diagnosis of Schizophrenia – CORRIGENDUM. Epidemiology and Psychiatric Sciences, 2011, 20, 379-379.	3.9	0
64	Psychosocial interventions for the promotion of mental health and the prevention of depression among older adults. Health Promotion International, 2011, 26, i85-i107.	1.8	146
65	Reported stigma and discrimination by people with a diagnosis of schizophrenia. Epidemiology and Psychiatric Sciences, 2011, 20, 193-204.	3.9	71
66	European comparisons between mental health services. Epidemiology and Psychiatric Sciences, 2011, 20, 15-18.	3.9	15
67	Psychosocial Interventions for the Prevention of Depression in Older Adults: Systematic Review and Meta-Analysis. Journal of Aging and Health, 2011, 23, 387-416.	1.7	103
68	Supporting decision-making processes for evidence-based mental health promotion. Health Promotion International, 2011, 26, i140-i146.	1.8	14
69	Cognitive components of social capital and mental health status among older adults: A population-based cross-sectional study. Scandinavian Journal of Public Health, 2011, 39, 757-765.	2.3	42
70	Reducing the Silent Burden of Impaired Mental Health. Journal of Health Communication, 2011, 16, 59-74.	2.4	32
71	Predictors of stigmatizing attitudes towards people with mental disorders in a general population in Finland. Nordic Journal of Psychiatry, 2011, 65, 125-132.	1.3	49
72	Growth in Infancy and Childhood and Hospitalization for Personality Disorders in Adulthood: The Helsinki Birth Cohort Study. Journal of Personality Disorders, 2011, 25, 620-633.	1.4	8

#	Article	IF	CITATIONS
73	Attitudes towards people with mental disorders: the psychometric characteristics of a Finnish questionnaire. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 265-273.	3.1	24
74	Use of psychotropic drugs before pregnancy and the risk for induced abortion: population-based register-data from Finland 1996-2006. BMC Public Health, 2010, 10, 383.	2.9	16
75	Incidence of cancer and statin usageâ€"Record linkage study. International Journal of Cancer, 2010, 126, 279-284.	5.1	140
76	Incidence of cancer and antidepressant medication: Record linkage study. International Journal of Cancer, 2010, 126, 285-296.	5.1	48
77	Costâ€utility of treatment of bulimia nervosa. International Journal of Eating Disorders, 2010, 43, 596-602.	4.0	22
78	Increase in the duration of antidepressant treatment from 1994 to 2003: a nationwide populationâ€based study from Finland. Pharmacoepidemiology and Drug Safety, 2010, 19, 1186-1193.	1.9	18
79	Beta-Blocker Supplementation of Standard Drug Treatment for Schizophrenia. Schizophrenia Bulletin, 2010, 36, 1079-1080.	4.3	15
80	Prenatal origins of hospitalization for personality disorders: The Helsinki Birth Cohort Study. Psychiatry Research, 2010, 179, 226-230.	3.3	20
81	Five-year mortality of Finnish schizophrenia patients in the era of deinstitutionalization. Social Psychiatry and Psychiatric Epidemiology, 2009, 44, 135-142.	3.1	29
82	The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 2009, 109, 10-14.	2.0	175
83	Community mental-health services and suicide rate in Finland: a nationwide small-area analysis. Lancet, The, 2009, 373, 147-153.	13.7	148
84	11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11) Tj ETQq0	0 Q <u>rg</u> BT /0	Overlock 10 7
85	Neuroleptic-induced movement disorders in a naturalistic schizophrenia population: diagnostic value of actometric movement patterns. BMC Neurology, 2008, 8, 10.	1.8	11
86	Reductions in Postdischarge Suicide After Deinstitutionalization and Decentralization: A Nationwide Register Study in Finland. Psychiatric Services, 2007, 58, 221-226.	2.0	59
87	Organisational downsizing and increased use of psychotropic drugs among employees who remain in employment. Journal of Epidemiology and Community Health, 2007, 61, 154-158.	3.7	83
88	Real-world effectiveness of pharmacological treatments in schizophrenia. European Psychiatry, 2007, 22, S55-S56.	0.2	0
89	Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: A double-blind randomised placebo controlled 6-month trial. BMC Family Practice, 2007, 8, 34.	2.9	61
90	Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clinical Pharmacology, 2007, 7, 5.	2.5	92

#	Article	IF	Citations
91	Reductions in Postdischarge Suicide After Deinstitutionalization and Decentralization: A Nationwide Register Study in Finland. Psychiatric Services, 2007, 58, 221-226.	2.0	19
92	P.2.c.016 Antidepressant use and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort. European Neuropsychopharmacology, 2006, 16, S321.	0.7	0
93	Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ: British Medical Journal, 2006, 333, 224.	2.3	317
94	Call for a European Guidelines Institute. British Journal of Psychiatry, 2006, 188, 193-193.	2.8	7
95	Glutamatergic drugs for schizophrenia. The Cochrane Library, 2006, , CD003730.	2.8	51
96	Europe's mental health strategy. BMJ: British Medical Journal, 2006, 333, 210.	2.3	7
97	Antidepressants and the Risk of Suicide, Attempted Suicide, and Overall Mortality in a Nationwide Cohort. Archives of General Psychiatry, 2006, 63, 1358-67.	12.3	228
98	The mortality of young offenders sentenced to prison and its association with psychiatric disorders: a register study. European Journal of Public Health, 2006, 16, 193-197.	0.3	41
99	Restraint and seclusion in psychiatric inpatient wards. Current Opinion in Psychiatry, 2005, 18, 555-559.	6.3	86
100	Actometry in measuring the symptom severity of restless legs syndrome. European Journal of Neurology, 2005, 12, 385-387.	3.3	14
101	Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurology, 2005, 5, 5.	1.8	88
102	The characteristics of suicides within a week of discharge after psychiatric hospitalisation – a nationwide register study. BMC Psychiatry, 2005, 5, 32.	2.6	44
103	Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. BMC Medicine, 2005, 3, 15.	5.5	42
104	Comparison of Large Versus Smaller Randomized Trials for Mental Health-Related Interventions. American Journal of Psychiatry, 2005, 162, 578-584.	7.2	32
105	Mental disorders in prison populations aged 15-21: national register study of two cohorts in Finland. BMJ: British Medical Journal, 2005, 330, 1364-1365.	2.3	11
106	Actometry and Barnes Akathisia Rating Scale in neuroleptic-induced akathisia. European Neuropsychopharmacology, 2005, 15, 39-41.	0.7	21
107	European psychiatric treatment guidelines: is the glass half full or half empty?. European Psychiatry, 2005, 20, 554-558.	0.2	14
108	Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research, 2005, 72, 225-234.	2.0	189

#	Article	IF	Citations
109	Topiramate Add-On in Treatment-Resistant Schizophrenia. Journal of Clinical Psychiatry, 2005, 66, 1012-1015.	2.2	86
110	Safety Reporting in Randomized Trials of Mental Health Interventions. American Journal of Psychiatry, 2004, 161, 1692-1697.	7.2	74
111	Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 1099-1107.	4.8	43
112	Lower limb motor restlessness in Asperger's disorder, measured using actometry. Psychiatry Research, 2004, 128, 63-70.	3.3	10
113	Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of Clinical Epidemiology, 2004, 57, 1124-1130.	5.0	166
114	Prevalence of Neuroleptic-Induced Movement Disorders in Chronic Schizophrenia Inpatients. American Journal of Psychiatry, 2004, 161, 160-163.	7.2	133
115	Quantitative rest activity in ambulatory monitoring as a physiological marker of restless legs syndrome: A controlled study. Movement Disorders, 2003, 18, 442-448.	3.9	25
116	Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial. BMC Family Practice, 2003, 4, 7.	2.9	93
117	A practice guideline for treatment of eating disorders in children and adolescents. Annals of Medicine, 2003, 35, 488-501.	3.8	39
118	New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet, The, 2003, 361, 1581-1589.	13.7	667
119	New generation versus conventional antipsychotics. Lancet, The, 2003, 362, 404-405.	13.7	5
120	Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological Psychiatry, 2003, 54, 1241-1248.	1.3	173
121	No association between micrometer-sized particles in human cerebrospinal fluid and schizophrenia. Neuroscience Letters, 2003, 349, 68-70.	2.1	7
122	Antisocial Violent Offenders With Attention Deficit Hyperactivity Disorder Demonstrate Akathisia-Like Hyperactivity in Three-Channel Actometry. Journal of Neuropsychiatry and Clinical Neurosciences, 2003, 15, 194-199.	1.8	12
123	Decrease of Energy Expenditure Causes Weight Increase in Olanzapine Treatment - A Case Study. Pharmacopsychiatry, 2002, 35, 124-126.	3.3	42
124	Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophrenia Research, 2002, 56, 1-10.	2.0	93
125	Neopterin and Macrophage Inflammatory Protein- $\hat{11}$ in the Cerebrospinal Fluid of Schizophrenic Patients: No Evidence of Intrathecal Inflammation. Neuropsychobiology, 2002, 46, 169-172.	1.9	16
126	Differential response to right unilateral ECT in depressed patients: impact of comorbidity and severity of illness [ISRCTN39974945]. BMC Psychiatry, 2002, 2, 2.	2.6	9

#	Article	IF	Citations
127	Randomized controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatrica Scandinavica, 2002, 105, 243-251.	4.5	48
128	Reply to "Efficacy of 17beta-Estradiol on Depression: Is Estrogen Deficiency Really Necessary?". Journal of Clinical Psychiatry, 2002, 63, 451-452.	2.2	0
129	Dropout rates in randomised antipsychotic drug trials. Psychopharmacology, 2001, 155, 230-233.	3.1	156
130	Association of Schizophrenia With Low Maternal Body Mass Index, Small Size at Birth, and Thinness During Childhood. Archives of General Psychiatry, 2001, 58, 48.	12.3	223
131	Associations between childhood living circumstances and schizophrenia: a population-based cohort study. Acta Psychiatrica Scandinavica, 2001, 104, 356-360.	4.5	21
132	Estrogen Deficiency in Severe Postpartum Depression. Journal of Clinical Psychiatry, 2001, 62, 332-336.	2.2	214
133	Newer atypical antipsychotic medication versus clozapine for schizophrenia. The Cochrane Library, 2000, , CD000966.	2.8	46
134	Influence of Methodology on Outcomes of Randomised Clozapine Trials. Pharmacopsychiatry, 2000, 33, 54-59.	3.3	13
135	Current antipsychotic dose correlates to mononuclear cell counts in the cerebrospinal fluid of psychotic patients. Psychiatry Research, 2000, 93, 13-19.	3.3	13
136	Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2000, 24, 911-922.	4.8	61
137	Much to improve: A survey of controlled Nordic schizophrenia trials. Nordic Journal of Psychiatry, 2000, 54, 105-108.	1.3	1
138	Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot trial. Schizophrenia Research, 2000, 41, 197.	2.0	2
139	Are UK consultants interested in pragmatic trials for those with schizophrenia?. Schizophrenia Research, 2000, 41, 233.	2.0	2
140	Cerebrospinal fluid angiotensin-converting enzyme (ACE) correlates with length of illness in schizophrenia. Schizophrenia Research, 2000, 41, 335-340.	2.0	20
141	Efficacy of $\hat{l}^2$ -blocker supplementation for schizophrenia: a systematic review of randomized trials. Schizophrenia Research, 2000, 41, 341-347.	2.0	15
142	Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis. International Journal of Psychiatry in Clinical Practice, 1999, 3, 159-169.	2.4	9
143	The impact of pregnancy and puerperium on panic disorder: A review. Journal of Psychosomatic Obstetrics and Gynaecology, 1999, 20, 59-64.	2.1	45
144	The Cochrane Schizophrenia Group. Revista Brasileira De Psiquiatria, 1999, 21, 106-108.	1.7	0

#	Article	lF	CITATIONS
145	Evidence of Clozapine's Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials. American Journal of Psychiatry, 1999, 156, 990-999.	7.2	275
146	A longitudinal study of cerebrospinal fluid angiotensin-converting enzyme in neuroleptic-treated schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1997, 21, 591-599.	4.8	8
147	Neuropeptide FF-Like Immunoreactivity in Human Cerebrospinal Fluid of Chronic Pain Patients and Healthy Controls. Peptides, 1997, 18, 923-927.	2.4	15
148	Elevated plasma vasopressin and normal cerebrospinal fluid angiotensin-converting enzyme in chronic pain disorder. Biological Psychiatry, 1996, 40, 994-999.	1.3	11
149	The effect of clozapine on the course of illness in chronic schizophrenia. International Clinical Psychopharmacology, 1996, 11, 265-272.	1.7	29
150	Plasma and Cerebrospinal Fluid Interleukin-1 $\hat{l}^2$ and Interleukin-6 in Hospitalized Schizophrenic Patients. Neuropsychobiology, 1994, 30, 20-23.	1.9	39
151	Elevated angiotensin-converting enzyme (kininase II) in the cerebrospinal fluid of neuroleptic-treated schizophrenic patients. Schizophrenia Research, 1993, 9, 77-82.	2.0	41
152	Interf eron-α as Adjuvant Treatment in Chronic Schizophrenia. Neuropsychobiology, 1993, 28, 192-196.	1.9	7
153	Elevated angiotensin-converting enzyme (kininase II) in the cerebrospinal fluid of schizophrenic patients. Schizophrenia Research, 1992, 6, 139.	2.0	O
154	Psychosocial interventions for prevention of depression in older people. The Cochrane Library, 0, , .	2.8	4
155	Temporary Separation from Parents in Early Childhood and Serious Personality Disorders in Adult Life. Journal of Personality Disorders, 0, , 1-12.	1.4	O